Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease

Lancet

Volumn 349, Issue 9068, 1997, Pages 1805-1809

  Iyo, Masaomi ^a,b   Namba, Hiroki ^a,c   Fukushi, Kiyoshi ^a   Shinotoh, Hitoshi ^a,d   Nagatsuka, Shinichiro ^a,e   Suhara, Tetsuya ^a   Sudo, Yasuhiko ^a   Suzuki, Kazutoshi ^a   Irie, Toshiaki ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c CHIBA CANCER CENTER   (Japan)

^d CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; CARBON 11;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; BRAIN CORTEX; BRAIN CORTEX LESION; BRAIN MAPPING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; ENZYME ACTIVITY; FRONTAL CORTEX; HUMAN; HYDROLYSIS; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSORIMOTOR CORTEX; TEMPORAL CORTEX;

EID: 0030910311     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09124-6     Document Type: Article

References (28)

1. Carlsson A. Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. Gerontology 1987; 33: 159-67.
2. Gottfries CG. Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 1985; 86: 245-52.
3. Hansen LA, De Teresa R, Davies P, Treey RD. Neocortical morphometry, lesion counts and choline acetyltransferase level in the age spectrum of Alzheimer's disease. Neurology 1988; 38: 48-54.
4. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1427-29.
5. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40: 503-09.
6. Wilcock GK, Esiri MM, Bowen DM, Smith CCT. Alzheimer's disease: correlation of cortical choline acetyltransferase activity with severity of dementia and histological abnormalities. J Neurol Sci 1982; 57: 407-17.
7. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-60.
8. Martin EM, Wilson RS, Penn RD, Fox JH, Clasen RA, Savoy RN. Cortical biopsy results in Alzheimer's disease correlation with cognitive deficits. Neurology 1987; 37: 1201-04.
9. 11C-methyl]-benztropine. Synapse 1990; 5: 213-23.
10. Pappata S, Tavitian B, Traykov L, et al. In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 1996; 67: 876-79.
11. Weinberger DR, Gibson R, Coppola R, et al. The distribution of cerebral muscarinic acetylcholine receptor in vivo in patients with dementia. Arch Neurol 1991; 48: 169-76.
12. Davies P, Maloney AFJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; ii: 1403.
13. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994; 21: 801-08.
14. Irie T, Fukushi K, Namba H, et al. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 1996; 37: 649-55.
15. Namba H, Irie T, Fukushi K, Iyo M. In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. Brain Res 1994; 667: 278-82.
16. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
17. McKhan G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology 1984; 35: 939-44.
18. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-72.
19. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman L. Cerebral perfusion imaging in Alzheimer's disease. Arch Neurol 1987; 44: 165-68.
20. Jagust WJ, Budinger T, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 1987; 44: 258-62.
21. 123I]iodo-amphetamine super-early SPECT. Ann Nucl Med 1996; 10: 161-64.
22. 14C]deoxyglucose method for the measurement of local cerebral glucose utilisation. J Neurochem 1977; 28: 897-16.
23. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in human with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6: 371-88.
24. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyryl-cholinesterase in the aged human central nervous system. J Neurochem 1986; 47: 263-77.
25. Arai H, Kosaka K, Muramoto O, Moroji T, Iizuka R. A biochemical study of cholinergic neurons in the post-mortem brains from the patients with Alzheimer-type dementia. Rinsho Shinkeigaku 1984; 24: 1128-35.
26. 99mTc]-d,1-HMPAO in the human brain after intracarotid bolus injection: a kinetic analysis. J Cereb Blood Flow Metab 1988; 8: S13-22.
27. 99mTc]-d,1-HMPAO SPECT study. J Neurol Neurosurg Psychiatry 1994; 57: 285-95.
28. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-59.